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Abstract Kynurenine pathway, the quantitatively main
branch of tryptophan metabolism, has been long been
considered a source of nicotinamide adenine dinucleotide,
although several of its products, the so-called kynurenines,
are endowed with the capacity to activate glutamate re-
ceptors, thus potentially influencing a large group of
functions in the central nervous system (CNS). Migraine, a
largely unknown pathology, is strictly related to the glu-
tamate system in the CNS pathologic terms. Despite the
large number of studies conducted on migraine etio-
pathology, the kynurenine pathway has been only recently
linked to this disease. Nonetheless, some evidence suggests
an intriguing role for some kynurenines, and an exploratory
study on the serum kynurenine level might be helpful to
better understand possible alterations of the kynurenine
pathway in patients suffering from migraine.
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Introduction
L-Tryptophan is an essential amino acid having in its
chemical structure an indole substitute on the b carbon.
The principal role of tryptophan in humans is as a con-
stituent of protein synthesis, even if it is also the precursor
of two important metabolic pathways such as serotonin and
kynurenine synthesis [1]. Although serotonin synthesis
accounts for approximately 5–10 % of tryptophan catabo-
lism, it has been a topic of intense research given its well-
known action as a neurotransmitter [2, 3]. In particular,
serotonergic mechanisms have been involved both in mood
disorders and in migraine pathophysiology [4]. In fact, the
main pharmacological approach to mood disorders is rep-
resented by the selective serotonin reuptake inhibitors
(SSRI); whereas triptans, the 5-HT receptors agonists, are
considered a first-line treatment in acute migraine [5]. The
kynurenine pathway (KP), accounting for more than 90 %
of the tryptophan metabolism, has received less attention,
even though it generates neuroactive compounds that are
able to interact with glutamate receptors in the central
nervous system (CNS) [6]. In the past few decades, the role
of KP has been intensively studied in several psychiatric
disorders as well as in neurodegenerative diseases [7, 8].
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More recently, scientists report a possible involvement of
kynurenine metabolites in migraine pathophysiology [9].
Migraine has a complex pathophysiology in which both
central and peripheral components of the trigeminal pain
pathway play a central role [10, 11]. The trigemino-vas-
cular activation during the attack has largely been de-
scribed, and recently the brainstem nuclei, called
‘‘migraine generators’’, have been reported to be involved
in migraine. Moreover, a series of destabilizing events
within the brain trigger a cortical spreading depression
(CSD), responsible for the aura phenomena and for tri-
geminal activation [12]. The role of glutamate is heavily
supported both in the trigemino-vascular as well as in
brainstem nuclei activation, and furthermore in the CSD
initiation and propagation [13]. Some of the KP metabo-
lites have been demonstrated to interact both with
ionotropic and metabotropic glutamate receptors [6].
Therefore, their possible role in the pathophysiology of
migraine will be extensively reviewed in this paper.
The L-tryptophan kynurenine pathway
The KP accounts for more than 90 % of the essential
aminoacid L-tryptophan metabolism in humans, in parallel
with serotonin production. The KP of tryptophan metabo-
lism generates neuroactive compounds that are able to in-
teract with glutamate receptors in the CNS [6]. The first
step of the pathway is the conversion of tryptophan into N-
formylkynurenine, catalyzed by either indolamine-2,3-
dioxygenase (IDO) or tryptophane-2,3-dioxygenase (TDO)
(Fig. 1). Both enzymes are present in the CNS, although
their expression levels are lower than in peripheral cells
where TDO is mainly expressed in liver [14]. N-For-
mylkynurenine is then converted by formamidase into
kynurenine (KYNU), which is hydroxylated into 3-hy-
droxykynurenine (3-HK) by kynurenine monoxygenase
(KMO), or alternatively, transaminated into kynurenic acid
(KYNA), by types 1, 2 and 3 kynurenine aminotransferases
(KAT1-3), or transformed into anthranilic acid (ANA) by
kynurenines. 3-HK is sequentially transformed into 3-hy-
droxyanthranilic acid (3-HANA), and quinolinic acid
(QUINA), or transaminated to xanthurenic acid (XA) [6].
Cinnabarinic acid is a by-product of the pathway, which
derives from the condensation of two molecules of
3-HANA [15]. In the last step of the KP, QUINA is con-
verted into the coenzymes nicotinamide adenine dinu-
cleotide (NAD), and NAD phosphate (NADP), by a
phosphoribosyltransferase (Fig. 1). The KP enzymatic re-
actions are located in macrophages, microglial cells and,
partially, in astrocytes [16]. KYNA and QUINA have been
the subject of extensive investigation since they have been
shown to interact with ionotropic glutamate receptors.
QUINA has been found in nanomolar concentrations in the
CNS, and acts as an orthosteric agonist at the GluN2
subunits of N-methyl-D-aspartate (NMDA) receptors [17].
Moreover, it might regulate endogenous glutamate release
and uptake inhibition and lipid peroxidation [18]. In con-
trast, KYNA acts as a competitive antagonist at the glycine
site on the GluN1 subunit of NMDA receptors, thereby
inhibiting NMDA receptor function [19]. KYNA also in-
hibit the kainate (GluK) and the amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) glutamate re-
ceptors (GluR), and has a non-competitive inhibitory action
on the a7-nicotinic acetylcholine (nACh) receptors [20].
Similarly to QUINA, it has been found in the CNS at
nanomolar concentrations, and exerts a possible neuro-
protective effect [21]. It has been demonstrated to reduce
the neuronal loss in excitotoxic, ischemia-induced and
neuronal injuries [22].
To date, 3-HK and 3-HANA have mainly been studied,
since they have been shown to induce neurotoxic effects by
increasing oxidative stress and the production of free
radicals or through excitotoxicity [23, 24]. In fact, both the
molecules autoxidize under physiological conditions pro-
ducing highly reactive hydroxyl radicals, even if these
properties are partially balanced by their related an-
tioxidant capacity to scavenge peroxyl radicals [25].
Moreover, cinnabarinic acid has been reported as an
orthosteric agonist of mGlu4 receptors with no activity at
other mGlu receptor subtypes endowed with neuroprotec-
tive activity [15]. The production of XA from 3-HK lowers
the concentration of the latter, reducing its neurotoxicity
[26]. Moreover, XA has been recently demonstrated to be a
putative agonist of metabotropic glutamate receptors 2/3
(mGlu2/3) [27].
Glutamate relevance in migraine pathophysiology
Migraine is a common, recurrent, and disabling primary
headache disorder affecting up to 20 % of the popula-
tion with a female/male ratio of 3/1 [28]. The central
clinical symptoms of migraine are represented by attacks of
unilateral throbbing headache, generally followed by nau-
sea, photophobia and phonophobia, and worsened by
physical activity. Before the headache attacks, about one-
third of migraineurs experience an aura, a focal neuro-
logical disturbance clinically manifested as visual, sensi-
tive or motor symptoms due to a cortical spreading
depression (CSD) originating in the occipital cortex [29].
CSD is a slowly progressing wave of depolarization fol-
lowed by a long-lasting suppression of neuronal activity
and excitability propagating through the cortex. The exact
physiopathology of migraine is still not fully understood,
and the brain events that initiate the migraine attacks
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remain unclear. The most well-established and accepted
migraine pathophysiological mechanisms involve (1) the
peripheral sensitization of the trigemino-vascular system
(TS) [11], (2) the central sensitization of the caudal tri-
geminal nucleus (TNC) [30], as well as the (3) activation of
brainstem generator nuclei [31], and (4) the development of
the CSD [32]. To be precise, the order of appearance of
these phenomena is not necessarily the same as described
in the text.
Glutamate plays a key role in the migraine patho-
physiological mechanisms, even if studies conducted to
compare plasma and platelet glutamate concentrations in
migraineurs and in controls lead to conflicting results [13,
33]. Nevertheless, systematically elevated glutamate levels
lead to spontaneous headache in humans, and also to sig-
nificant craniofacial muscle sensitization [34]. The impor-
tance of glutamate has been reported at many levels of the
nervous system; therefore, the comprehension of its role in
migraine might be crucial for the development of novel
therapeutic approaches.
1. The peripheral trigeminal nociceptors sensitization
results from the following process: the vasodilatation
of the dural and pial blood vessels arises and acts as a
trigger mechanism, leading to a neuropeptides release
from perivascular trigeminal primary nociceptors,
thereby inducing sterile neurogenic inflammation
[35]. In fact, the released calcitonin gene-related
peptide (CGRP), substance P and neurokinin A
stimulate the trigeminal first-order neurons, leading
to their peripheral sensitization [36]. This process is
clinically reflected by the throbbing nature of the pain,
and its worsening during activities that increase
intracranial pressure. The glutamate receptors are
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Fig. 1 The kynurenine
pathway. 1.a Indoleamine-
pyrrole 2,3-dioxygenase; 1.b
tryptophan 2,3-dioxygenase; 2
arylamine formamidase; 3
kynurenine aminotransferase; 4
kynurenine 3-hydroxylase; 5
kynureninase; 6
3-hydroxyanthranilic acid 3,4-
dioxygenase; 7 autoxidation
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expressed in the dorsal root, the TG primary sensory
afferents and together with the a7-nACh receptors, and
are involved in nociceptive signaling [9]. A recent
study reports that glutamate dysregulation in the TG is
a novel mechanism for peripheral sensitization of the
craniofacial region [37]. Similar is the sensitization of
craniofacial muscles in the rat, caused by elevated
glutamate levels in the TG, is in part NMDA-mediated,
and driven by peripheral processes [37].
2. The TNC is located in the medulla and in the superior
part of the spinal cord, and receives the central
projections of the trigeminal first-order neurons, whose
cell bodies are located in the trigeminal ganglion (TG).
Conversely, the first-order neurons peripheral projec-
tions innervate the intracranial pain structures. The
activation of the second-order trigeminal neurons
involves glutamate as the main neurotransmitter [30].
Glutamate levels are increased in the TNC after
stimulation of the first-order trigeminal neurons, and
both the NMDA receptors and other glutamate recep-
tors are expressed in the TNC [38]. NMDA receptors
mediate the activation of the second-order neurons,
even if other glutamate receptors antagonists con-
tribute to their inhibition [39]. Moreover, even the a7-
nACh receptors presynaptically modulate the activa-
tion of the second-order neurons and therefore the
transmission of nociceptive information to the CNS
[40]. The activation of second-order trigeminal neu-
rons leads to the central sensitization of the TNC,
clinically revealed by cutaneous allodynia of the head
and face [30]. The glutamate receptors are involved in
the central sensitization process: the increase in
extracellular glutamate levels directly correlates with
sensory threshold changes on the face of rats [38].
3. The activation of specific brainstem nuclei, called
‘‘migraine generators’’, has been well demonstrated
during a migraine attack [41]. These nuclei belong to
the pain regulatory structures, and include the dorsal
raphe nucleus (DRN), the nucleus raphe magnus
(NRM), the locus coeruleus (LC), and the periaque-
ductal gray matter (PAG) [42]. Therefore, a loss of
nociception regulatory function of the brainstem nuclei
may be involved in migraine pathophysiology [43]. In
the past few decades, glutamatergic neurotransmission
has been reported involved in the activation of
migraine generators. In fact, glutamate receptors
antagonist reduces the activity of NRM, glutamate
levels increase in LC after sciatic nerve or neuronal
stimulation in PAG [44].
4. The last potential trigger mechanism of migraine is the
CSD, a slowly progressing wave of depolarization
followed by a long-lasting suppression of neuronal
activity and excitability and accompanied by slowly
spreading cortical hypoperfusion. CSD is largely
considered the neuronal basis for the aura phenomenon
[12]. Although the CSD initiation of a migraine attack
process still remains unclear, CSD itself has been
demonstrated to initiate the trigeminal sensitization by
the activation of the trigemino-vascular afferent and
the induction of sterile inflammation (i.e., increased
blood flow and protein extravasation) in the dura mater
[45]. Glutamate and its receptors perhaps initiate a
CSD [46]. Administration of glutamate triggers a CSD
and suddenly dilates pial arterioles in the mouse
cortex, while NMDA receptor antagonists, but not non-
NMDA receptors antagonists, can reduce the number
of CSD waves and decrease the permeability of the
BBB during CSD [46]. Furthermore, recent data
demonstrate that NR2B-containing NMDA receptors
are key mediators of CSD, and that selective changes
in several glutamate receptors binding sites (NMDA,
AMPA, and kainate) are related to the delayed
excitatory phase after CSD [47]. Therefore, gluta-
matergic neurotransmission is also linked to trigeminal
activation by its initiation and propagation of the CSD.
KP metabolites in migraine
L-Kynurenine
Tryptophan metabolism to L-kynurenine, catalyzed by the
KP rate-limiting enzyme indolamine 2,3-dioxygenase
(IDO), is stimulated by pro-inflammatory cytokines such as
interferon-c (IFN-c), and inhibited by interleukin-10 (IL-
10), tumor growth factor-b (TGF-b), and IL-4 [48]. As
KYNU can cross the blood brain barrier (BBB), and about
60 % of its brain concentration comes from the periphery,
peripheral inflammation is likely to increase central KYNU
levels [49]. Both systemic and central immune stimulation,
including cytokine-induced IDO activation, are believed to
contribute to the cerebral KP activation in neurological
disorders [6]. Some studies report a decrease in IL-4 serum
levels in migraineurs, and an increase in the IL-10 levels
[50, 51]. Moreover, tryptophan depletion is known both to
compromise immune responses, and to intensify photo-
phobia and other symptoms in migraine patients [52]. The
IDO over-expression stimulated by pro-inflammatory cy-
tokines may result in a decrease of serotonin availability in
parallel to an increase of KYNU synthesis [9]. Although
serotonin production is deficient in patients suffering from
migraine, KYNU itself has been demonstrated to act as a
vasodilator activating soluble guanylylcyclase and cyclic
GMP (GC-cGMP), adenylyl cyclase and cyclic AMP (AC-
cAMP) [48, 53]. Therefore, considering the possible
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involvement of IDO activity in migraine pathogenesis, the
evaluation of its genetic polymorphisms in patients might
help to better elucidate the KP association with migraine.
Moreover, the serum KYNU/TRP ratio, used as an indirect
index of IDO activity, has never been studied in migraine
patients, and might represent a useful tool for the charac-
terization of IDO activity role in migraine [54].
Kynurenic acid
Kynurenic acid acts in the brain as a glycine-site NMDA
receptors competitive antagonist. It also acts at the gluta-
mate site of the NMDA receptors, antagonizes the a7-
nACh receptors, and selectively activates the G-protein
coupled receptor GPR35 [55]. KYNA neuroprotective and
anticonvulsive properties have been reported in animal
models of neurodegenerative diseases [48]. KYNA is not
transported across the BBB, and its levels in the brain are
determined by the local synthesis from KYNU. The
transformation is catalyzed by several kynurenine amino-
transferases (KATs), of which KAT-II is the principal en-
zyme producing KYNA, expressed solely in astrocytes
[56]. Glial cells further release KYNA in the extracellular
compartment. Although the KYNA re-uptake processes
have still not been identified, the probenecid-sensitive or-
ganic anion transporters 1 and 3 (OAT 1, 3) have been
involved in its active removal from the extracellular
compartment [55]. In migraine, antinociceptive effects of
KYNA have been reported in both the first- and the second-
order trigeminal nociceptors. Moreover, KYNA reduces
the activation of migraine generators, and inhibits CSD
[48]. KYNA antiglutamatergic activity might be the neu-
robiological basis of the CSD inhibition. In fact, both the
NMDA receptor antagonist dizocipiline and KYNA are
able to reduce the number of CSD waves, and to decrease
the permeability of the BBB during CSD [57]. Moreover,
glutamate levels are increased during CSD. KYNA inhibits
CSD both in the cerebellum and in the neocortex, and in-
creased KYNA levels are found in rat brain after a trig-
gered CSD [58]. Sole KYNU systemic administration
reduces CSD frequency in female rats, whereas in males,
the same effect occurs after co-administration of probene-
cid, the difference regulated by the influence of ovarian
hormones [59]. The suppressive effect on CSD is related to
an increase in cerebral levels of KYNA. These data suggest
that KYNA might offer a new approach for migraine with
aura treatment (Fig. 2). KYNA modulates second-order
nociceptors in the TS (Fig. 2). In fact, in animal models of
migraine, the administration of KYNA or its analogues,
and the co-administration of KYNU with probenecid sig-
nificantly mitigates the central sensitization of the TNC
[60–62]. At peripheral nociceptors level, KYNA shows
antinociceptive effects as well (Fig. 2). Both the systemic
and the local KYNA administration reduce nociception and
allodynia [63, 64]. Moreover, KAT expression is reduced
in a migraine model such as the electrical stimulation of the
trigeminal ganglion (TG) [65]. A KYNA derivative inhibits
the activation of the primary sensory fibers, and therefore
the subsequent release of CGRP [62]. Beside the peripheral
glutamate receptors, two other possible KYNA targets are
represented by peripheral a7-nACh receptors and the
G-protein-coupled receptor-35 (GPR35) (Fig. 2), involved
in nociceptive signaling [66, 67]. Fejes-Szabo´ et al. [67]
suggest that a KYNA derivative can dose-dependently
modulate the changes in neurochemical markers of acti-
vation and sensitization of the trigeminal system, possibly
acting on peripheral and central glutamate or a7-nicotinic
acetylcholine receptors. Independently of its biochemical
actions at receptors, KYNA also shows antioxidant fea-
tures, which are linked to its ability to scavenge hydroxyl,
superoxide anion and other free radicals [68]. Therefore,
KYNA and its derivatives represent a novel and useful
therapeutic approach to migraine pharmacological
treatment.
3-Hydroxykynurenine
Kynurenine is oxidized into 3-HK by kynurenine-3-
monoxygenase (KMO). While KYNA is produced mainly
in astrocytes, 3-HK and QUINA are synthesized by acti-
vated monocytic cells [16]. 3-HK generates toxic free
radicals, leading to neurodegeneration and neuronal apop-
tosis [69]. Moreover, 3-HK also generates superoxide and
hydrogen peroxide promoting oxidative protein damage
[25]. In addition to enhanced IDO activity, pro-inflamma-
tory cytokines also enhance the activity of KMO, which in
turn enhances 3-HK production and the excitotoxic de-
generative arm of the pathway [49]. During a migraine
attack, a number of neurobiological changes occur within
the neuroinflammation process, such as cytokine-induced
stress, oxidative and nitrosative stress caused by perox-
ynitrates, and release of free radicals throughout arachi-
donic acid formation. A study demonstrates a significant
increase of malondialdehyde plasma levels, the final pro-
duct of lipid peroxidation, as marker of oxidative stress in
migraineurs [70]. The authors suggest a possible novel
migraine treatment base on the antioxidant defence system.
3-HK, with its oxidative potential and its enhanced pro-
duction during inflammation, represents a possible
mechanism underlying these observations.
Xanthurenic acid
Xanthurenic acid (XA), a metabolite of 3-hydrox-
ykynurenine that has been described as a signaling mole-
cule in the mammalian brain, has recently been identified
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as a selective endogenous group II (mGlu2 and mGlu3)
metabotropic glutamate (mGlu) receptor ligand [26, 27].
XA is formed from 3-HK transamination catalyzed by
KAT. This pathway is considered a detoxifying process
since it reduces the 3-HK concentration. Moreover, the
activation of mGlu3 in mice is required to reduce the
NMDA excitotoxic neuronal death, whereas mGlu2 acti-
vation may damage neurons exposed to toxic insults [71].
Therefore, the potential neuroprotective role of XA in
migraine should be elucidated.
Anthranilic acid and 3-hydroxyanthranilic acid
Anthranilic acid, another by-product of kynurenine meta-
bolism, is virtually an upstream metabolite of KMO, since it
is produced from KYNU transamination by kynureninase.
3-HANA can derive either from the hydrolysis of 3-HK or
the oxidation of ANA [54]. It auto-oxidizes under physio-
logical conditions, producing hydrogen peroxide and highly
reactive hydroxyl radicals [6]. 3-HANA can also cause
neuronal damage thus provoking primary or secondary ex-
citotoxicity [72]. 3-HANA has immune-regulatory proper-
ties, potentially relevant for autoimmune diseases [73]. The
involvement of these metabolites in neuroprotective/neuro-
toxic processes, and therefore their hypothetical implication
in migraine, has not been explored.
Cinnabarinic acid
Cinnabarinic acid (CA) is a by-product of KP, which
derives from the condensation of two molecules of
3-HANA. Its biological function is largely unknown [15,
74, 75]. CA harbors two carboxyl groups and a neutral
free amino group, which is the basic requirement for an
interaction with the orthosteric site of excitatory ami-
noacid receptors. CA acts as a weak agonist at mGlu4
metabotropic glutamate receptors [15]. CA affords sig-
nificant protection against NMDA toxicity via activation
of mGlu4 [15]. An enhanced formation of CA has been
reported during inflammation [15]. Similarly to XA, it
may protect neurons against the harmful effect of pro-
inflammatory cytokines or endogenous excitotoxins.
Moreover, by its capability to activate mGlu4 receptors
and aryl hydrocarbon receptors, CA drives immune sys-
tems to an immunosuppressive phenotype [74, 75].
Quinolinic acid
The observation that intracerebro-ventricular injection
of QUINA causes seizure activity in mice gave the first
evidence that KP metabolites have central effects [76].
QUINA acts as an orthosteric NMDA receptors with
excitatory and neurotoxic properties, resulting in the
induction of nitric oxide synthase and excessive nitric
oxide-mediated free radical damage [8]. In direct in-
tracerebral administration QUINA leads to neuronal
death [77]. In contrast with its glutamatergic properties,
QUINA reduces CSD in the rat cortex, probably due to
NMDA desensitization (Fig. 2) [78]. Despite of the
extended number of studies conducted on QUINA, its
role in migraine pathogenesis needs to be further
investigated.
Fig. 2 Connection between
kynurenine pathway metabolites
and known involved pathways
in migraine. NMDA-R N-
methyl-D-aspartate receptor; a7-
nAch-R alpha-7 nicotinic
receptor; GPR35 G-protein-
coupled receptor 35; KYNA
kynurenic acid; QUINA
quinolinic acid; CA cinnabarinic
acid; 3-HK
3-hydroxykynurenine; 3-HANA
3-hydroxyanthranilic acid
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Conclusions
Migraine possesses one of the highest incidence among all
disease affecting the worldwide population [28]. Despite
the high number of affected patients and the efforts in
pharmacogenetic understanding of this multifactorial dis-
ease, pharmacotherapy is still inadequate to mitigate phy-
sical sufferings of many migraineurs [79].
The role of glutamate, a major excitatory neurotrans-
mitter in the CNS, is widely recognized in migraine
pathogenesis [13]. Critical hallmarks of migraine, such as
trigemino-vascular activation, central sensitization and
cortical spreading depression involve glutamate. Along one
branch of tryptophan metabolism, the kynurenine pathway
furnishes a series of compounds able to interact with glu-
tamate receptors, and some of these molecules have re-
cently been linked to migraine [9]. As with the findings
obtained in other neurological disorders, where an initial
imbalance of a few kynurenine metabolites led to the ex-
ploration of the role of the entire pathway in the disease
pathophysiology, we suggest that these first studies on
kynurenine metabolites in migraine may lead to a wider
understanding of its biochemical mechanisms.
A study of the overall scenario of kynurenines in pa-
tients suffering from migraine would be helpful to find out
alternative options in the research on the etio-pathogenetic
mechanisms underlying migraine. Our ongoing studies will
point on both the genotypic and the phenotypic profiles of
the kynurenine pathway in migraine.
Conflict of interest None.
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